Tauriga Sciences Inc. Retains FAMR to Commence Bidding Process on Several Identified U.S. Government Contracts
October 09 2020 - 11:12AM
InvestorsHub NewsWire
NEW
YORK, NY -- October 9, 2020 -- InvestorsHub NewsWire
-- Tauriga Sciences, Inc.
(OTCQB: TAUG)
(“Tauriga” or the “Company”), a revenue generating, diversified
life sciences company, with a proprietary line of functional
“supplement” chewing gums (Flavors: Pomegranate, Blood Orange,
Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two
ongoing Biotechnology initiatives, today announced that it has
retained Federal Award Management Registration (“FAMR”) to commence
the bidding process on several identified potential U.S. Government
Contracts (“Contracts”). These potential Contracts are
presented by the Department of Defense (“DOD”). FAMR is
an independent consulting firm that specializes in: Registrations,
Certifications, and Federal
Contracting.
On October 06, 2020,
the Company announced that it was officially approved to operate as
a U.S. Government Vendor. The Company’s Commercial &
Government Entity (“CAGE”) Code # is: 8QXV4 with an expiration date
of October 01, 2021.
ABOUT TAURIGA SCIENCES
INC.
Tauriga Sciences, Inc.
(TAUG)
is a revenue generating, diversified life sciences company, engaged
in several major business activities and
initiatives. The company manufactures and distributes
several proprietary retail products and product lines, mainly
focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles
market segment. The main product line, branded as
Tauri-Gum™, consists of a proprietary supplement chewing gum that
is Kosher certified, Halal certified, and Vegan Formulated (CBD
Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG
Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant) &
(Vitamin C + Zinc “Immune Booster” Tauri-Gum™ Flavor: Pear
Bellini). The Company’s commercialization strategy
consists of a broad array of retail customers, distributors, and a
fast-growing E-Commerce business segment (E-Commerce website:
www.taurigum.com). Please visit our corporate website, for
additional information, as well as inquiries,
at http://www.tauriga.com
Complementary to the
Company’s retail business, are its two ongoing biotechnology
initiatives. The first one relates to the development of
a Pharmaceutical grade version of Tauri-Gum™, for nausea regulation
(specifically designed to help patients that are subjected to
ongoing chemotherapy treatment). On March 18, 2020, the
Company announced that it filed a provisional U.S. patent
application covering its pharmaceutical grade version of
Tauri-Gum™. The Patent, filed with the U.S.P.T.O. is
Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND
METHODS OF TREATMENT”. The second one relates to a
collaboration agreement with Aegea Biotechnologies Inc. for the
co-development of a rapid, multiplexed, Novel Coronavirus
(COVID-19) test with superior sensitivity and
selectivity.
On October 7, 2020 the
Company disclosed a Strategic Alliance with Think BIG, LLC, Social
Impact Startup Founded by CJ Wallace, Son of Christopher “The
Notorious B.I.G. ” Wallace.
The Company is
headquartered in New York City and operates a regional office in
Barcelona, Spain. In addition, the Company operates a
full time E-Commerce fulfillment center located in LaGrangeville,
New York.
DISCLAIMER --
Forward-Looking Statements
This press release
contains certain “forward-looking statements” as defined by the
Private Securities Litigation Reform Act of 1995 which represent
management’s beliefs and assumptions concerning future events.
These forward-looking statements are often indicated by using words
such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,”
“believes,” or plans, and may include statements regarding
corporate objectives as well as the attainment of certain corporate
goals and milestones. Forward-looking statements are based on
present circumstances and on management’s present beliefs with
respect to events that have not occurred, that may not occur, or
that may occur with different consequences or timing than those now
assumed or anticipated. Actual results may differ materially from
those expressed in forward looking statements due to
known and unknown risks and uncertainties, such as are not
guarantees of general economic and business conditions, the ability
to successfully develop and market products, consumer and business
consumption habits, the ability to consummate successful
acquisition and licensing transactions, fluctuations in exchange
rates, and other factors over which Tauriga has little or no
control. Many of these risks and uncertainties are discussed in
greater detail in the “Risk Factors” section of Tauriga’s Form 10-K
and other filings made from time to time with the Securities and
Exchange Commission. Such forward-looking statements are made only
as of the date of this release, and Tauriga assumes no obligation
to update forward-looking statements to reflect subsequent events
or circumstances. You should not place undue reliance on these
forward-looking statements.
Contact:
CONTACT
INFORMATION
Tauriga Sciences, Inc.
555 Madison Avenue, 5th Floor
New York, NY 10022
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Instagram:
@taurigum
Twitter:
@SethMShaw
Corp.Website: www.tauriga.com
E-Commerce
Website: www.taurigum.com
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Apr 2023 to Apr 2024